| Drug Type Autologous CAR-T | 
| Synonyms CD7-Specific CAR-T Cells(Hebei Senlangbio), DVHH NS7CAR-T(Hebei Senlangbio), KO7CAR + [8] | 
| Target | 
| Action inhibitors | 
| Mechanism CD7 inhibitors(T-cell antigen CD7 inhibitors) | 
| Therapeutic Areas | 
| Inactive Indication | 
| Originator Organization | 
| Active Organization | 
| Inactive Organization- | 
| License Organization- | 
| Drug Highest PhasePhase 2 | 
| First Approval Date- | 
| RegulationOrphan Drug (United States) | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| T-cell Acute Lymphoblastic Leukemia/Lymphoma | Phase 2 | China  | 30 Sep 2025 | |
| T-Cell Lymphoma | Phase 1 | China  | 01 May 2022 | |
| CD7 Positive T-Cell Leukemia | Phase 1 | China  | 01 Oct 2020 | |
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | Phase 1 | China  | 01 Oct 2020 | |
| Precursor T-cell lymphoblastic lymphoma | Phase 1 | China  | 01 Oct 2020 | |
| Refractory T Acute Lymphoblastic Leukemia | Phase 1 | China  | 01 Oct 2020 | |
| Refractory T Lymphoblastic Lymphoma | Phase 1 | China  | 01 Oct 2020 | |
| T-cell acute lymphoblastic leukemia in relapse | Phase 1 | China  | 01 Oct 2020 | |
| Adult Lymphoblastic Lymphoma | Clinical | China  | 10 May 2021 | |
| CD7 Positive Acute Myeloid Leukemia | Clinical | China  | 10 May 2021 | 
| Phase 1/2 | 53 | hjdbgbfhwr(uxtoohyznr) = sbxfumogrm rsqdvdvpsf (jytvoagjeu ) View more | Positive | 15 Nov 2022 | |||
| Phase 1 | 15 | KO7CAR T-cells+Fludarabine Phosphate+Cyclophosphamide | wognvihukl(umdqwwvxzf) = yawcanajoz zdkvtsaqml (buqnhpgrcl ) View more | Positive | 12 May 2022 | ||
| Phase 1 | 20 | brmhnhsdpe(lphknkmbce) = 2pts neurotoxicity aksuzkpfvs (finpzhgvcu ) View more | Positive | 02 May 2022 | |||
| Phase 1 | Mixed phenotype acute leukemia CD7 Positive | 5 | xrrgkhjwyi(knnryekqrc) = wmiprxetzp qwzvndocgj (qpjxayydve ) View more | Positive | 05 Nov 2021 | 





